Which regimen is effective in treating r/rDLBCL in patients ineligible for allogeneic stem cell transplantation (ASCT)?

Updated: Jun 12, 2019
  • Author: Shipra Gandhi, MBBS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Polatuzumab vedotin, an antibody-drug conjugate targeting CD79b, has shown significantly improved outcomes for r/rDLBCL in patients ineligible for allogeneic stem cell transplantation (ASCT) when combined with bendamustine and rituximab (BR) compared with BR alone. [78]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!